Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma

• Published in: The European respiratory journal Vol. 50; no. 2; p. 1700019
• Main Authors: Pretolani, Marina, Soussan, David, Poirier, Isabelle, Thabut, Gabriel, Aubier, Michel
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society Journals Ltd 01.08.2017; European Respiratory Society
• Subjects: Adult; Anti-Asthmatic Agents - therapeutic use; Asthma; Asthma - diagnosis; Asthma - epidemiology; Asthma - physiopathology; Asthma - therapy; Cohort Studies; Cross-Sectional Studies; Deoxyribonucleic acid; Disease Progression; DNA; Emergency Service, Hospital - statistics & numerical data; Eosinophilia; Eosinophilia - diagnosis; Eosinophilia - etiology; Female; France - epidemiology; Hospitalization - statistics & numerical data; Humans; Immunoglobulin E; Leukocytes (eosinophilic); Life Sciences; Longitudinal Studies; Male; Middle Aged; Monoclonal antibodies; Omalizumab - therapeutic use; Respiratory function; Respiratory Function Tests - methods
• ISSN: 0903-1936; 1399-3003; 1399-3003
• DOI: 10.1183/13993003.00019-2017

The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter. Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More than 60% of patients with severe asthma were therapy-uncontrolled at entry, and 152 of them were being treated with omalizumab. In addition, patients with asthma who had the highest eosinophilia levels (>300/mm 3 ) had shorter asthma duration, lower lung function, and higher rates of severe exacerbations and unacceptable asthma control than patients with lower eosinophil counts. Longitudinal analyses performed in 427 patients with asthma with at least three differential blood cell counts demonstrated that both eosinophil numbers and eosinophil increase over time were associated with the number of exacerbations occurring until the next visit and with Juniper score. Studies with the COBRA cohort will help to improve knowledge concerning the risk and biological factors associated with asthma severity and to better understand their influence on the disease trajectory.